Velocity Clinical Research

11/12/2025

Velocity Clinical Research welcomes Andrew (Drew) Reina as Chief Revenue Officer (CRO).

Drew brings more than two decades of global clinical research experience, having led high-performing commercial teams and strategic partnerships at both Fortrea (formerly Labcorp Drug Development) and PPD, where he oversaw a $1B+ global portfolio of Phase II–IV studies.

“This has been a challenging year for clinical research in many ways,” said Paul Evans, President & CEO of Velocity. “Andrew’s experience at Fortrea brings deep CRO-centric leadership to our team and helps position Velocity not just as an exceptional site network, but as a strategic partner — particularly for biotech and leading pharma companies.”

“Sponsors and CROs increasingly rely on MCRCs to accelerate speed to market and reduce burden on both sites and patients,” added Drew Reina. “Velocity is exceptionally positioned to meet those needs, and I’m energized by the opportunity to contribute to its continued growth and impact.”

As Velocity enters a new phase of consolidation and growth, Drew’s appointment reinforces our mission to deliver high-quality, patient-focused research through a holistic operations and commercial strategy, helping Sponsors and CROs bring new treatments to patients faster, with greater consistency and quality.

Learn more about Drew's appointment and Velocity’s integrated site network: https://velocityclinical.com/velocity-appoints-former-fortrea-executive-andrew-reina-as-chief-revenue-officer

11/11/2025

This Veteran's Day, we pay tribute to the brave men and women who have selflessly served. Your sacrifices and dedication inspire us all.

Join us in saluting our heroes and standing together in appreciation and respect.

10/07/2025

Generative AI is reshaping clinical research—but its true power lies in the data behind it. In his latest op-ed, Tyler Beasley explores how Velocity’s integrated site network and smart infrastructure make our data AI-ready from day one, unlocking real-world impact for patients, Sponsors, and CROs.

Highlights:
- 70+ owned sites across the U.S. & Europe, with LATAM expansion underway
- 3× faster site activation than CROs
- 1.5M+ patient database with 20% outside traditional care centers
- VISION platform: AI-powered tools improving recruitment, retention & equity
- VIP dashboards: Real-time insights for Sponsors

Velocity is building the future of clinical trials—faster, smarter, and more equitable.

Read the full op-ed: https://velocityclinical.com/op-ed-how-data-is-driving-genai-solutions-in-clinical-trials/

10/01/2025

09/18/2025

The loss of lean muscle mass has long been a concern for patients using GLP-1 therapies. New results from the Regeneron Phase 2 COURAGE trial, led by Julio Rosenstock, MD, at Velocity’s site in Dallas, TX, point to a potential solution.

The study indicates that combining semaglutide with trevogrumab (anti-GDF8/anti-myostatin) helped prevent about half of the lean mass loss typically associated with GLP-1 therapy, while enhancing fat loss.

As the lead investigator for the trial, Dr. Rosenstock stated in the Regeneron press release: “These complete 26-week COURAGE results demonstrate a meaningful opportunity to preserve muscle mass while enhancing fat loss.”

Also noted: “Numerical improvements in metabolic and lipid parameters, secondary and exploratory endpoints, were seen across all treatment groups, including improvements in waist circumference, blood pressure, cholesterol, triglycerides and A1C.”

Read the full press release:
https://investor.regeneron.com/news-releases/news-release-details/results-phase-2-courage-trial-demonstrating-potential-improve

08/22/2025

Heading to Orlando for the SCRS Global Site Solutions Summit? Discover how Velocity is accelerating research programs for Sponsors and improving the clinical trial experience for participants.

At this event:
• Paul Evans
• Sara Smiley, DO, FACP
• Craig Koch
• Jenn Carl
• Dan Robitaille
• Paul Kergides
• Grant Miller

Connect with our team before the show and visit us at booth 219!

08/21/2025

In 2025, clinical trials supported by Velocity contributed to the FDA approval of 10 new products, as well as two updated product approvals.

Since the start of 2024, our sites have supported research for 20 products that earned U.S. FDA approval. In total, Velocity sites have played a role in the development of 75 approved treatments and vaccines.

Patient centricity is about more than improving the trial experience. When we can deliver high-quality data at scale, life-changing therapies can reach the market faster.

08/20/2025

Julio Rosenstock, MD, was the lead author of Phase 2 trial results evaluating orforglipron, an oral GLP-1 receptor agonist, published in Diabetes, Obesity and Metabolism.

The study found that orforglipron doses of 12 mg and higher significantly improved β-cell function and insulin sensitivity in participants with type 2 diabetes (T2D). These results support orforglipron’s potential as a meaningful oral treatment option for people living with T2D.

Congratulations to our Dallas site and the entire research team for their contributions to this important work.

Read the full article: https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.70022

08/18/2025

Congratulations to two of our U.K. sites for recently achieving FPI for two trials!

Our High Wycombe site randomized the first patient in a global chronic kidney disease trial. The site was greenlit and screened its first participant within about two weeks of contract ex*****on. Well done to Judith Mackay, MBBS, PhD, MRCP, and team!

Earlier this year, our North London site became the first in the U.K. to screen and randomize a patient in a chronic spontaneous urticaria trial. Congratulations to Kamran Hussain, MBBS, and team on this achievement!

08/14/2025

AI is everywhere—but in clinical trials, it can’t just be everywhere. At Velocity, we’ve built a rigorous AI governance framework to ensure that every model we use is not only powerful, but also trustworthy, secure, and compliant.

We evaluated leading frameworks from across the industry—including Gartner’s AI TRiSM and Microsoft’s Responsible AI principles—to create a model that fits the unique demands of clinical research. The result? A system that helps us decide which AI tools are fit for purpose—and which ones aren’t.

From vendor tools to in-house models like VISION, every AI system at Velocity must pass our TRiSM-based assessment before it’s approved for use. Because in our world, efficiency can’t come at the cost of ethics, safety, or patient trust.

Read the full article to learn how we’re making AI work responsibly in clinical trials: https://velocityclinical.com/not-all-ai-belongs-in-clinical-trials-heres-how-we-decide-which-models-do/

07/31/2025

William Cromwell, MD, FAHA, FNLA, shares his perspective on how targeted treatments are reshaping cardiometabolic research, and why now is an ideal moment to leverage expertise at scale.

As a leader of the Cardiometabolic CARE Council, and Principal Investigator at our site in Durham, NC, Dr. Cromwell is a longtime thought leader in lipoprotein disorders and cardiovascular disease.

Learn more about Velocity's Cardiometabolic CARE Council: https://velocityclinical.com/cardiometabolic-care-council/

07/30/2025

Velocity’s ability to deliver at scale continues to improve speed and enrollment performance for trials worldwide.

For a recent trial, Velocity sites contributed over one-third of all participants, and outpaced other sites in screening, enrollment, and participants delivered per site.

Learn more about Velocity at Scale: velocityclinical.com/scale